<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962440</url>
  </required_header>
  <id_info>
    <org_study_id>NN8640-4237</org_study_id>
    <secondary_id>2016-000096-24</secondary_id>
    <secondary_id>U1111-1178-1251</secondary_id>
    <nct_id>NCT02962440</nct_id>
  </id_info>
  <brief_title>A Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Dosing in Healthy Male Subjects</brief_title>
  <official_title>A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Subcutaneous Dosing in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of the trial is to investigate the absorption,
      metabolism and excretion of somapacitan after single subcutaneous dosing in healthy male
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total amount of [3H]-somapacitan related material excreted in urine (% of dose)</measure>
    <time_frame>Assessed up to 35 days after trial product administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total amount of [3H]-somapacitan related material excreted in faeces (% of dose)</measure>
    <time_frame>Assessed up to 35 days after trial product administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total amount of [3H]-somapacitan related material excreted in expired air (% of dose)</measure>
    <time_frame>Assessed up to 35 days after trial product administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total recovery of administered 3H label (sum of urine, faeces and expired air)</measure>
    <time_frame>Assessed up to 36 days after trial product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood to plasma ratio of [3H]-somapacitan related material</measure>
    <time_frame>Assessed up to 36 days after trial product administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Somapacitan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somapacitan</intervention_name>
    <description>All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing [3H]-somapacitan</description>
    <arm_group_label>Somapacitan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, aged 45-64 years (both inclusive) at the time of signing informed consent

          -  Body mass index (BMI) 20.0-29.9 kg/m^2 (both inclusive)

          -  Considered to be generally healthy based on the medical history, physical examination,
             and the results of vital signs, electrocardiogram and clinical laboratory tests
             performed during the screening visit, as judged by the investigator

        Exclusion Criteria:

          -  Male of reproductive age who or whose partner(s) is not willing to use adequate
             contraceptive methods (adequate contraceptive measures as required by local regulation
             or practice) for at least 4 months after dosing or male who is not willing to refrain
             from donating semen for at least 4 months after dosing. Acceptable forms of prevention
             include complete sexual abstinence, surgically sterilisation, that the subject uses a
             condom during intercourse or that the partner practices adequate contraception (risk
             of pregnancy must be lower than 1%).

          -  Use of prescription or non-prescription products, including herbal products and
             non-routine vitamins, within 14 days prior to screening. Occasional use of paracetamol
             is permitted.

          -  Any blood draw in excess of 25 mL in the past 30 days, or donation of blood or plasma
             in excess of 400 mL within the 90 days preceding screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

